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Abstract 
Neonatal hypoglycemia (NH) is a common concern among term and late preterm infants in the 
first day of life. Current NH management follows the American Academy of Pediatrics’ 
guideline to treat with intravenous dextrose if blood sugar levels fall below a set threshold, which 
in many cases requires admission to the neonatal intensive care unit (NICU). Oral dextrose gel is 
currently an effective, inexpensive, and safe treatment for hypoglycemia in the pediatric and 
adult population, and researchers are exploring its use in the neonatal population.  This prompted 
the following research question: in otherwise healthy late preterm and term newborns at risk for 
NH, how does the use of oral dextrose gel in addition to oral feedings, as compared to the current 
standard of care of oral feedings alone, affect blood sugar homeostasis in the first day of life?  To 
answer this research question, upon completing a review of the literature and obtaining IRB 
approval on site, an evidence based practice change was implemented that included the addition 
of oral dextrose gel to the existing NH protocol in a tertiary hospital in the southwestern United 
States with a level III NICU and a busy delivery service.  
 Keywords: neonatal hypoglycemia treatment, neonatal hypoglycemia oral dextrose gel, 
neonatal blood glucose homeostasis, neonatal hypoglycemia management, neonatal glucose 
metabolism, oral dextrose gel versus intravenous dextrose, neonatal hypoglycemia protocol 
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Oral Dextrose Gel in the Treatment of Neonatal Hypoglycemia 
 Neonatal hypoglycemia (NH) is a common problem in the newborn period that usually 
resolves on its own in the first few days of life. Not all infants who have low blood sugar levels 
are symptomatic; therefore many hospitals have NH protocols that screen infants based on risk 
factors. Infants with critically low blood glucose levels defined as <30mg/dL, if left untreated for 
a prolonged period of time, can have significantly impaired motor and mental development at 18 
months of age, although current research has yet to determine the blood glucose level and 
duration threshold at which this irreversible damage occurs. 
Background & Significance 
 Neonatal hypoglycemia is the leading cause for NICU admissions among late preterm 
and term infants (Bennett, Headtke, & Rowe-Telow, 2015). It is commonly seen in otherwise 
healthy newborns by one to two hours of life, and is often asymptomatic and transient with blood 
glucose levels as low as 30mg/dL. While NH is considered a normal part of transition to extra-
uterine life that usually resolves by the first day of life, in some infants blood glucose 
homeostasis takes longer regardless of the infant being asymptomatic and feeding well.  
 Historically, treatment has followed the American Academy of Pediatrics’ (AAP) 
recommendation to feed the infant and recheck blood glucose in one hour (Committee on Fetus 
and Newborn & Adamkin, 2011). If the repeat blood glucose is less than 25mg/dL despite oral 
feeding, the infant will require treatment with IV dextrose, which means that the infant will be 
admitted to the NICU for treatment. Not only does this separation interfere with maternal-infant 
interaction in the first day of life, it can also lead to decreased breastfeeding rates (Bennett et al., 
2015). Many existing hospital NH protocols specify blood glucose screening procedures, and if 
after a specified amount of time the infant’s blood glucose remains out of range despite feeding 
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well and being asymptomatic, the AAP recommends IV dextrose administration even though a 
blood glucose level of 45mg/dL on the first day of life is not nearly as significant for 
neurological damage as on the third day of life, where the blood sugar levels should be greater 
than 70mg/dL on average (Brown & Rozance, 2016).  
Problem Statement 
 Persistent NH, when left untreated, has been linked to poor neurological outcomes such 
as seizures, learning deficits, cerebral palsy and mental retardation (Bennett, Fagan, 
Chaharbakhshi, Zamfirova, & Flicker, 2016).  It is estimated that 15% of otherwise healthy 
newborns are affected by neonatal hypoglycemia (Mosalli, 2014). Certain factors place newborn 
infants at a higher risk of developing hypoglycemia in the first day of life, and those risk factors 
include being born to a diabetic mother (IDM), late prematurity (34-37 weeks gestation), post 
maturity (> 41 weeks gestation), small for gestational age (less than the 10th percentile in weight 
for gestational age), large for gestational age (greater than the 90th percentile in weight for 
gestational age), and other reasons after birth such as poor feeding (Harris, Weston, & Harding, 
2012).  
 According to the March of Dimes Perinatal Data Center (2011), 19% of special care 
nursery (SCN) or neonatal intensive care (NICU) admissions were late preterm infants (34-37 
weeks gestation) with hospital length of stay (LOS) ranging from 5.9 to 9.8 days. Nearly six 
percent of late preterm infants admitted to SCN or NICU units had the admitting diagnosis of 
NH, and no other complications that required them to be in the NICU for treatment. In the 
facility where this evidence based practice change was implemented, 49 infants who were 
otherwise healthy were admitted to the NICU for NH treatment in 2017 alone. 
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 It is estimated that the hospital cost for a NICU stay for NH for an otherwise healthy late 
preterm or term infant can range from $37,137 to $51,083 (March of Dimes Perinatal Data 
Center, 2011). A regular newborn nursery admission for a healthy late preterm or term newborn 
is estimated to be only $4415 (Rawat et al., 2016). In the facility where this evidence based 
practice change was implemented, the cost of caring for these 49 infants who were otherwise 
healthy could be estimated to be around 2.5 million dollars in 2017. This prompted the following 
PICOT question:  in otherwise healthy late preterm and term newborns at risk for NH, how does 
the use of oral dextrose gel in addition to oral feedings, as compared to the current standard of 
care of oral feedings alone, affect blood sugar homeostasis in the first day of life?   
Search Strategy 
 In order to answer the aforementioned PICOT question, the following databases were 
searched: The Cochrane Library, PubMed, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), and ASU Libraries OneSearch. Keywords included: neonatal 
hypoglycemia, neonatal hypoglycaemia, neonatal hypoglycemia treatment, neonatal 
hypoglycemia oral dextrose gel, neonatal blood glucose homeostasis, neonatal hypoglycemia 
management, neonatal glucose metabolism, oral dextrose gel versus intravenous dextrose, 
neonatal hypoglycemia protocol. Both American and English spellings of keywords were used. 
Filters were set to include research articles with publication dates within the last five years. The 
strategy also included ancestral searching and reviews of gray literature to determine the overall 
incidence of NH and to identify differences in NH incidence related to different risk factors, in 
addition to different treatment strategies for NH. 
 The initial search for “neonatal hypoglycaemia” in the Cochrane Library yielded 196 
articles. When the search was limited to “neonatal hypoglycaemia AND treatment”, the results 
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were narrowed down to 159 articles. A further limitation to only include “neonatal 
hypoglycaemia AND dextrose gel” resulted in 16 articles. After close examination, only one 
systematic review in the Cochrane Library was applicable to this project’s topic and retained for 
further review (Appendix A).  
 PubMed was searched using the keywords “neonatal hypoglycemia management”, which 
resulted in 714 possible articles. After adding additional limits to only include articles from the 
most recent five years and peer-reviewed articles, while changing the search terms to “neonatal 
hypoglycemia oral dextrose gel” the search yielded seven articles, all of which were retained for 
further review (Appendix B). 
 A search using CINAHL using the key words “neonatal hypoglycemia treatment” yielded 
11 results that were published within the past five years. After adding additional filters for peer 
reviewed articles and research, one article remained. A separate CINAHL keyword search using 
“neonatal hypoglycemia oral dextrose gel” yielded two articles, and both were retained for 
review (Appendix C).  
 Lastly, ASULibraries OneSearch was used with the following keywords “neonatal 
hypoglycemia oral dextrose”. Limitations that were added were publication date within past five 
years and scholarly and peer-reviewed journal articles. This yielded 146 articles, however, the 
majority of the articles focused on gestational diabetes and implications for pregnant women 
rather than hypoglycemia in the neonatal population (Appendix D). 
 Eleven final articles were selected for critical appraisal: one systematic review, six 
randomized controlled trials, and four retrospective chart reviews.  
Evidence Synthesis 
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 While a review of the literature confirms that there is no specific plasma glucose 
concentration or duration of NH that can predict permanent neurological injury in at risk infants, 
the treatment for asymptomatic hypoglycemic newborns in the first day of life is up for debate 
(Committee on Fetus and Newborn & Adamkin, 2011). Until recently, NH has been treated by 
IV dextrose administration as recommended by the AAP (Bennett et al., 2016), but recent 
literature reviews show that oral dextrose gel is being investigated as a possible alternative 
treatment for NH.   
 A retrospective chart review pre- and post-implementation of oral dextrose gel in an NH 
treatment trial found that the primary admitting diagnosis to the NICU for NH decreased from a 
mean of 11% to 2% (Bennett et al., 2015). In a follow up study led by Bennett et al. (2016), the 
researchers found that using oral dextrose gel in addition to oral feeding reduced NICU 
admissions significantly for otherwise healthy newborns with transient NH. During a 14-month 
period, they noted a continued decrease in NICU admissions for NH among late preterm and 
term infants (Bennett et al., 2016).  
 Brown and Rozance (2016) noted that while in their study oral dextrose gel appeared to 
be effective in treating NH in asymptomatic term infants, they felt the same results likely would 
not apply to infants with symptomatic or severe NH. Their concern was that using oral dextrose 
gel in symptomatic infants might delay treatment with IV dextrose and lead to irreversible 
neurological damage (Brown & Rozance, 2016). 
 Harding et al. (2015) designed a randomized, placebo controlled trial that proposed the 
prevention of NH by giving oral dextrose gel to infants who are at risk for NH but are not 
currently experiencing low blood sugar levels. In a follow up study led by Hegarty et al. (2016), 
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prophylactic use of oral dextrose gel in at risk newborns resulted in fewer NICU admissions for 
NH compared to the placebo group.  
 The Sugar Babies Study, a randomized, double blind, placebo-controlled trial done in 
New Zealand, found that the addition of oral dextrose gel to oral feeding reduced the frequency 
of NH treatment failure leading to NICU admission for IV dextrose administration, as compared 
with placebo (Harris et al., 2013). 
 Another study found that 51% of term and late preterm infants who were considered to be 
at risk for developing NH in the first day of life became hypoglycemic, with 19% developing 
severe NH (Harris, Weston, & Harding, 2012). While this particular study did not discuss the use 
of oral dextrose gel as a possible non-invasive and alternative treatment for NH, the findings did 
underline the importance of routine screening protocols for at risk infants, as these infants are at 
significantly higher risk for developing NH especially when multiple risk factors are present. 
Harris et al. (2012) then used the findings of this study in subsequent research that specifically 
looked at the use of oral dextrose gel in NH treatment and prevention. 
 A Cochrane review led by Weston et al. (2016) found that the use of 40% oral dextrose 
gel reduced NICU admissions for NH and also reduced the frequency of mother-baby separation 
for NH treatment. The Cochrane review found no evidence of adverse effects of oral dextrose 
use during the neonatal period or at two years of age (Weston et al., 2016). 
 Mosalli (2014) found that at risk infants treated with oral dextrose gel were nearly twice 
as likely to achieve blood glucose homeostasis without needing additional interventions such as 
IV dextrose, as compared to their counterparts who received a placebo gel. 
 Another study led by Rawat et al. (2016) found that oral dextrose gel increased blood 
glucose levels in 74% of their study group, which led to reduced NICU admissions for IV 
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dextrose treatment. They also noted that exclusive breastfeeding rates improved from 19% to 
28% (Rawat et al., 2016). 
 While the use of oral dextrose gel may be an innovative and inexpensive solution to a 
long existing problem in the NICU, it is also important to note that there should be specific 
guidelines in place by what measure NH is diagnosed. Ly, Alexander, Akinmboni, Woo, and 
Driscoll (2016) set out to improve the diagnosis of NH by comparing point of care glucose 
(POCG) measurements with serum glucose measurements. What they found was that POCG 
measurements can vary greatly in accuracy, especially if blood glucose levels are below normal. 
If NH is suspected after a low POCG measurement, a confirmatory serum glucose test needs to 
be done to prevent delay in treatment (Ly et al., 2016). While the researchers could not 
determine a blood glucose threshold that would warrant immediate treatment besides oral 
feeding for an asymptomatic hypoglycemic newborn as the normal physiologic nadir is 
suspected to be around 30mg/dL, many hospital policies follow the AAP’s guideline to intervene 
at a blood glucose level <40mg/dL (Ly et al., 2016). 
 Recent studies are pointing towards oral dextrose gel being a safe, inexpensive, and non-
invasive alternative to the traditional IV dextrose treatment for NH for late preterm and term 
infants who otherwise have no other health concerns that would require treatment in the NICU. If 
indeed effective in helping achieve blood glucose homeostasis in the first day of life, not only 
could the inclusion of oral dextrose gel in existing NH policies potentially reduce unnecessary 
NICU admissions, it could also improve exclusive breastfeeding rates which is a Joint 
Commission perinatal core measure. 
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Purpose Statement 
 The purpose of this evidence based practice change is to add oral dextrose gel to the 
existing NH protocol as a safe, effective, and alternative treatment for NH, as compared to the 
previous standard of care in this particular setting where infants were admitted to the NICU to 
receive treatment with IV dextrose if oral feedings alone were not effective at achieving blood 
glucose homeostasis within a set time frame. This practice change will benefit the hospital by 
reducing healthcare costs associated with NICU admissions, and will also benefit infants and 
their families by shortening their hospital length of stay and therefore reduce associated 
healthcare expenses and by not separating the mother-infant dyad. 
Evidence Based Practice Model  
 The model chosen to guide the application of the synthesized evidence is the Model for 
Evidence-Based Practice Change (Rosswurm & Larrabee, 1999). This model illustrates the 
process for implementing research evidence into clinical practice in six specific steps (Appendix 
E). The first step is identification of a clinical issue, collecting internal and external data, and 
involving stakeholders. Research evidence supporting the proposed practice change was 
presented to the nursing research council, pediatricians, neonatologists, neonatal nurse 
practitioners, and hospital leadership.  
 The second step is to do a literature search to locate the best evidence. Step three is to 
critically analyze the evidence found in step two. The fourth step is to define practice change, 
and design a protocol. Using data from the literature search, an updated NH protocol was created 
that included an NH algorithm that outlined the steps nurses would take to identify infants at risk 
for NH and when to administer oral dextrose gel and the frequency of blood glucose checks. 
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The fifth step is implementation of the new protocol and evaluating the study. Evaluation of the 
study included comparing data of 27 infants post-implementation of the practice change who met 
risk factors for NH to 27 infants pre-implementation of the practice change. Care was taken to 
ensure that both groups had similar birth weights, gestational ages, risk factors, and initial blood 
glucose values to ensure a homogenous sample. Collecting data from a controlled setting such as 
one hospital will help determine the effectiveness of the evidence-based protocol, and using this 
model will allow for either modification or implementation of a practice protocol (Melnyk & 
Fineout-Overholt, 2015). Once the fifth step is finalized and conclusions and recommendations 
have been made, the final step is to maintain the change in practice, and to implement the change 
at other hospitals in the same system.  
Theoretical Model 
 The theoretical model that guided this project was Lewin’s Theory of Planned Change. 
Lewin’s change theory describes the process of effectively implementing change as a simple 
three-step process. Using Lewin’s Theory of Planned Change, the first step is identifying a 
problem (Shirey, 2013). The problem of NH treatment was identified and staff who would be 
taking care of infants that would qualify to receive oral dextrose gel were included in education 
about the practice change. This ensured staff readiness for the change. 
 The second stage of Lewin’s change theory looks at change as a process rather than an 
event (Shirey, 2013). In cooperation with hospital educators, the researcher ensured that staff 
was ready for the change, had a protocol in place, and implemented the practice change. 
 The third and last stage of Lewin’s theory is refreezing the change (Shirey, 2013). What 
this entails is ensuring that the change is sustained to continually improve outcomes. This was 
achieved by keeping communication lines open with the education department and staff, to 
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ensure that if there were any concerns they would be able to voice those concerns freely to 
ensure staff support throughout the practice change. Upon completion of this project, the results 
will be shared with the hospital staff and nursing research committee. 
Project Methods 
 Human subjects protection was obtained by the researcher from the hospital and 
university IRB prior to implementing the practice change. The researcher created an updated NH 
protocol along with an NH algorithm (Appendix F) that was displayed in multiple areas for easy 
reference. Nursing education was delivered via a voice-over PowerPoint created by the 
researcher and approved by the hospital nursing research committee to ensure consistency in the 
delivery of educational materials. This PowerPoint remains available on the hospital’s intranet 
and nurses providing care for infants in labor and delivery, newborn nursery, postpartum, and 
NICU were all educated on the use of the new algorithm. Questions regarding the new protocol 
were answered by the researcher directly to ensure consistency. Instruments used to obtain blood 
glucose levels were bedside glucometers that were maintained by the hospital laboratory staff 
following manufacturer recommendation, and nursing staff performed quality control tests daily. 
Data collection included chart reviews of 27 infants with similar inclusion criteria who received 
IV dextrose as treatment for NH in the previous year, and 27 infants post-implementation of the 
new protocol who met risk factors and/or received oral dextrose gel as initial treatment for NH. 
All statistical analysis was performed using SPSS v.24 (IBM Corp, 2016). 
Project Results 
  Upon data collection of 54 infants with similar demographical information, statistical 
analysis was performed to determine that this was a homogenous sample. While the gestational 
age range for this project included infants born at 34 weeks to greater than 41 weeks, both the 
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pre-implementation group and post-implementation group had similar gestational age means, 37 
2
7⁄  (SD=1.8) and 37 
5
7⁄  (SD=2) respectively. Additionally, birth weights in both groups ranged 
from 1630 gram to 5060 gram, with the mean birth weight in the pre-implementation group at 
3392 gram (SD=892) and in the post-implementation group 3056 gram (SD=697). Using a t-test, 
no statistically significant differences were identified between both groups’ demographics. 
 While none of the infants in the pre-implementation group received oral dextrose gel for 
NH treatment, all 27 infants in this group received IV dextrose infusion as treatment at a 
standard rate of 200mg/kg which is identical to the oral dextrose gel dose of 200mg/kg. Because 
the infants in this group all received IV dextrose this group has a 100% NICU admission rate. In 
the post-implementation group, 24 out of 27 infants received oral dextrose gel. While seven 
infants in the post-implementation group were admitted to the NICU for NH, chart reviews 
revealed that only two of those infants were admitted for NH and not other diagnoses that 
required admission to the NICU. This means that in the post-implementation group, the NICU 
admission rate for NH is 9% with a p<0.001 which indicates statistical significance. 
 The clinical significance of the two infants who received oral dextrose gel and were 
admitted to the NICU for treatment with IV dextrose is that they likely experienced refractory 
hypoglycemia secondary to being IDM, suggesting the possibility of hyperinsulinism, which 
complicates NH. 
Discussion 
 Upon data analysis, results will be presented to the nursing research committee to be 
shared with nursing staff. This project will be sustained in the hospital as it is evidence based 
practice, but slight modifications to the protocol will be made based on the results of this study, 
such as changing the post term age ranges to greater than 42 weeks (currently set at >41 weeks). 
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Conclusion 
 In the current hospital setting, the use of oral dextrose gel in addition to oral feedings was 
superior to treating NH as compared to oral feedings alone. The protocol created will be shared 
with other facilities, and larger studies need to be done to see if results are generalizable. 
Additionally, more research needs to be done to include small community or outlying hospitals 
that do not have NICUs, to see if the incorporation of oral dextrose gel in their existing NH 
protocols in newborn nurseries can also decrease the need for patient transfer to other hospitals 
for higher level of care in this particular population. 
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Appendix A 
Search Strategy 1: Cochrane Library 
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Appendix B 
Search Strategy 2: PubMed 
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Appendix C 
Search Strategy 3: EBSCOhost CINAHLplus with full text 
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Appendix D 
Search Strategy 4: ASU Libraries OneSearch 
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Appendix E 
Model for Evidence-Based Practice Change (Rosswurm & Larrabee, 1999)  
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Appendix F 
Neonatal Hypoglycemia Algorithm 
 
 
